Screener
Jazz Pharmaceuticals JAZZ Finite Lived Intangible Assets - Gross
Finite Lived Intangible Assets - Gross at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31, 2026 / Remaining Weighted-Average Useful Life(In years) | March 31, 2026 / Gross Carrying Amount | March 31, 2026 / Accumulated Amortization | March 31, 2026 / Net Book Value | December 31, 2025 / Gross Carrying Amount | December 31, 2025 / Accumulated Amortization | December 31, 2025 / Net Book Value |
|---|---|---|---|---|---|---|---|
| Acquired developed technologies | 6.6 | $8,092.6 | $(3,888.8) | $4,203.8 | $8,194.6 | $(3,765.1) | $4,429.5 |
| Manufacturing contracts | — | 1.3 | (1.3) | — | 12.6 | (12.6) | — |
| Trademarks | — | 2.9 | (2.9) | — | 2.9 | (2.9) | — |
| Total finite-lived intangible assets | $8,096.8 | $(3,893.0) | $4,203.8 | $8,210.1 | $(3,780.6) | $4,429.5 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's finite lived intangible assets - gross?
- Jazz Pharmaceuticals (JAZZ) reported finite lived intangible assets - gross of $8.1B in Q1 2026.
- How has Jazz Pharmaceuticals's finite lived intangible assets - gross changed year-over-year?
- Jazz Pharmaceuticals's finite lived intangible assets - gross increased by 2.5% year-over-year, from $7.9B to $8.1B.
- What is the long-term trend for Jazz Pharmaceuticals's finite lived intangible assets - gross?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's finite lived intangible assets - gross has grown at a 19.3% compound annual growth rate (CAGR), from $3.4B to $8.21B.
- What does finite lived intangible assets - gross mean?
- This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.
Ask your AI about Jazz Pharmaceuticals's finite lived intangible assets - gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude